Background Therapies to interrupt the progression of early coronavirus disease 2019 (Covid-
19) remain elusive. Among them, convalescent plasma administered to hospitalized patients …

Background Early administration of convalescent plasma obtained from blood donors who
have recovered from coronavirus disease 2019 (Covid-19) may prevent disease …

BACKGROUND: The efficacy of polyclonal high titer convalescent plasma to prevent serious
complications of COVID-19 in outpatients with recent onset of illness is uncertain …

Structured abstract for full paper Background After recovery from COVID-19, most patients
have anti-SARS-CoV-2 neutralizing antibodies. Their convalescent plasma could be an …

In a randomized clinical trial of 86 hospitalized COVID-19 patients comparing standard care
to treatment with 300mL convalescent plasma containing high titers of neutralizing SARS …

Background: While passive immunotherapy has been considered beneficial for patients with
severe respiratory viral infections, the treatment of COVID-19 cases with convalescent …

Background Polyclonal convalescent plasma may be obtained from donors who have
recovered from coronavirus disease 2019 (Covid-19). The efficacy of this plasma in …

Background Treatment of COVID-19 patients with plasma containing anti-SARS-CoV-2
antibodies may have a beneficial effect on clinical outcomes. We aimed to evaluate the …

Background Several randomised clinical trials have studied convalescent plasma for
coronavirus disease 2019 (COVID-19) using different protocols, with different severe acute …

The efficacy of convalescent plasma for coronavirus disease 2019 (COVID-19) is unclear.
Although most randomized controlled trials have shown negative results, uncontrolled …